Patient-derived organoids and mini-PDX for predicting MET^N375S-mutated lung cancer patient clinical therapeutic response.

ABSTRACT: Lung cancer as a molecularly and histologically high heterogonous disease, there is an urgent need to predict lung cancer patients' responses to anti-cancer treatment, and patient-derived organoids (PDOs) have been recognized as a valuable platform for preclinical drug screening. In this study, we successfully established 26 PDO lines from various subtypes of lung cancers including benign tumor, adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, large-cell carcinoma, and small-cell carcinoma. These PDOs were shown to retain the major genomic and histological characteristics of primary tumors and remain stable during long-term culture. With the help of targeted genomic sequencing, we found that lung cancer that harbors MET^N375S mutation is selectively sensitive to

SUBMITTER: Jiang M 

PROVIDER: S-EPMC11425092 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature